Jonathan Zalevsky

Company: Nektar Therapeutics

Job title: Chief R&D Officer

Seminars:

NKTR-358, a Modified IL-2 Pathway Agonist for Selective Expansion of Tregs in vivo 1:30 pm

Discussing the design of NKTR-358 using polymer chemistry Exploring NKTR-358’s mechanism of action and preclinical development Presenting Clinical highlights demonstrating Treg specificity and an optimal pharmacology profile for the treatment of autoimmune diseasesRead more

day: Day One | Track B | Morning